251
|
Cendón C, Du W, Durek P, Liu YC, Alexander T, Serene L, Yang X, Gasparoni G, Salhab A, Nordström K, Lai T, Schulz AR, Rao A, Heinz GA, Stefanski AL, Claußnitzer A, Siewert K, Dörner T, Chang HD, Volk HD, Romagnani C, Qin Z, Hardt S, Perka C, Reinke S, Walter J, Mashreghi MF, Thurley K, Radbruch A, Dong J. Resident memory CD4+ T lymphocytes mobilize from bone marrow to contribute to a systemic secondary immune reaction. Eur J Immunol 2022; 52:737-752. [PMID: 35245389 DOI: 10.1002/eji.202149726] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2021] [Revised: 01/27/2022] [Accepted: 03/01/2022] [Indexed: 11/12/2022]
Abstract
Resident memory T lymphocytes (TRM ) of epithelial tissues and the bone marrow protect their host tissue. To what extent these cells are mobilized and contribute to systemic immune reactions is less clear. Here we show that in secondary immune reactions to the measles-mumps-rubella (MMR) vaccine, CD4+ TRM are mobilized into the blood within 16 to 48 hours after immunization in humans. This mobilization of TRM is cognate: TRM recognizing other antigens are not mobilized, unless they cross-react with the vaccine. We also demonstrate through methylome analyses that TRM are mobilized from the bone marrow. These mobilized cells make significant contribution to the systemic immune reaction, as evidenced by their T-cell receptor Vβ clonotypes represented among the newly generated circulating memory T-cells, 14 days after vaccination. Thus, TRM of the bone marrow confer not only local, but also systemic immune memory. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Carla Cendón
- Cell Biology, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), an Institute of the Leibniz Association, Berlin, Germany
| | - Weijie Du
- Cell Biology, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), an Institute of the Leibniz Association, Berlin, Germany
| | - Pawel Durek
- Cell Biology, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), an Institute of the Leibniz Association, Berlin, Germany
| | - Yuk-Chien Liu
- Cell Biology, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), an Institute of the Leibniz Association, Berlin, Germany
| | - Tobias Alexander
- Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Lindsay Serene
- Department of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, USA
| | - Xinyi Yang
- Otto-Warburg-Laboratory, Computational Epigenomics, Max Planck Institute for Molecular Genetics, Berlin, 14195, Germany
| | - Gilles Gasparoni
- Department of Genetics, University of Saarland (UdS), Campus, Saarbrücken, 66123, Germany
| | - Abdulrahman Salhab
- Department of Genetics, University of Saarland (UdS), Campus, Saarbrücken, 66123, Germany
| | - Karl Nordström
- Department of Genetics, University of Saarland (UdS), Campus, Saarbrücken, 66123, Germany
| | - Tina Lai
- Cell Biology, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), an Institute of the Leibniz Association, Berlin, Germany
| | - Axel R Schulz
- Mass Cytometry, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), an Institute of the Leibniz Association, Berlin, Germany
| | - Anna Rao
- Cell Biology, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), an Institute of the Leibniz Association, Berlin, Germany
| | - Gitta A Heinz
- Therapeutic Gene Regulation, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), an Institute of the Leibniz Association, Berlin, Germany
| | - Ana L Stefanski
- Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Anne Claußnitzer
- Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Katherina Siewert
- Department of Chemical and Product Safety, German Federal Institute for Risk Assessment, Berlin, Germany
| | - Thomas Dörner
- Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Hyun-Dong Chang
- Cell Biology, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), an Institute of the Leibniz Association, Berlin, Germany.,Schwiete-Laboratory for Microbiota and Inflammation, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), an Institute of the Leibniz Association, Berlin, Germany
| | - Hans-Dieter Volk
- Institute for Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.,BIH Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Chiara Romagnani
- Innate Immunity, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), an Institute of the Leibniz Association, Berlin, Germany.,Medical Department / Gastroenterology, Infectiology and Rheumatology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Zhihai Qin
- Key Laboratory of Protein and Peptide Pharmaceuticals, Institute of Biophysics, Chinese Academy of Sciences, Bejing, China.,University of Chinese Academy of Sciences, Bejing, China.,Zhengzhou University, Zhengzhou, China
| | - Sebastian Hardt
- Center for Musculoskeletal Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Carsten Perka
- Center for Musculoskeletal Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Simon Reinke
- BIH Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Jörn Walter
- Department of Genetics, University of Saarland (UdS), Campus, Saarbrücken, 66123, Germany
| | - Mir-F Mashreghi
- Therapeutic Gene Regulation, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), an Institute of the Leibniz Association, Berlin, Germany.,BIH Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Kevin Thurley
- Systems Biology of Inflammation, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), an Institute of the Leibniz Association, Berlin, Germany.,Institute for Theoretical Biology, Humboldt University Berlin, Germany
| | - Andreas Radbruch
- Cell Biology, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), an Institute of the Leibniz Association, Berlin, Germany
| | - Jun Dong
- Cell Biology, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), an Institute of the Leibniz Association, Berlin, Germany
| |
Collapse
|
252
|
Ren D, Liu W, Ding S, Li Y. Protocol for generating human immune system mice and hydrodynamic injection to analyze human hematopoiesis in vivo. STAR Protoc 2022; 3:101217. [PMID: 35265863 PMCID: PMC8899045 DOI: 10.1016/j.xpro.2022.101217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Human immune system (HIS) mice provide a valuable platform to investigate and modulate human hematopoiesis development in vivo. Here, we describe detailed protocols for the construction of HIS mice, modulation of human hematopoiesis in vivo using hydrodynamic injection of plasmids encoding cytokines of interest, and flow cytometry analysis of humanization levels and human immune subsets. This approach can be easily applied to screen or verify factors that regulate human hematopoiesis and immune system. For complete details on the use and execution of this protocol, please refer to Cardoso et al. (2021) and Li et al. (2017). The protocol for construction of human immune system mice Detailed procedure for hydrodynamic injection Characterization of human immune subpopulations by flow cytometry In vivo modulation of human hematopoiesis
Collapse
|
253
|
Yang JHM, Ward-Hartstonge KA, Perry DJ, Blanchfield JL, Posgai AL, Wiedeman AE, Diggins K, Rahman A, Tree TIM, Brusko TM, Levings MK, James EA, Kent SC, Speake C, Homann D, Long SA. Guidelines for standardizing T-cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes. Eur J Immunol 2022; 52:372-388. [PMID: 35025103 PMCID: PMC9006584 DOI: 10.1002/eji.202049067] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2021] [Revised: 11/10/2021] [Accepted: 12/22/2021] [Indexed: 11/11/2022]
Abstract
Cytometric immunophenotyping is a powerful tool to discover and implement T-cell biomarkers of type 1 diabetes (T1D) progression and response to clinical therapy. Although many discovery-based T-cell biomarkers have been described, to date, no such markers have been widely adopted in standard practice. The heterogeneous nature of T1D and lack of standardized assays and experimental design across studies is a major barrier to the broader adoption of T-cell immunophenotyping assays. There is an unmet need to harmonize the design of immunophenotyping assays, including those that measure antigen-agnostic cell populations, such that data collected from different clinical trial sites and T1D cohorts are comparable, yet account for cohort-specific features and different drug mechanisms of action. In these Guidelines, we aim to provide expert advice on how to unify aspects of study design and practice. We provide recommendations for defining cohorts, method implementation, as well as tools for data analysis and reporting by highlighting and building on selected successes. Harmonization of cytometry-based T-cell assays will allow researchers to better integrate findings across trials, ultimately enabling the identification and validation of biomarkers of disease progression and treatment response in T1D.
Collapse
Affiliation(s)
- Jennie H. M. Yang
- Department of Immunobiology, Faculty of Life Sciences & Medicine, King’s College, London, UK
- National Institute of Health Research Biomedical Research Centre at Guy’s and St. Thomas’ National Health Service Foundation Trust, King’s College London, London, UK
| | - Kirsten A. Ward-Hartstonge
- Department of Surgery, University of British Columbia, Vancouver, California, USA
- BC Children’s Hospital Research Institute, Vancouver, California, USA
| | - Daniel J. Perry
- Department of Pathology, Immunology, and Laboratory Medicine, University of Florida Diabetes Institute, Gainesville, Florida, USA
| | - J. Lori Blanchfield
- Center for Translational Research, Benaroya Research Institute, Seattle, Washington, USA
| | - Amanda L. Posgai
- Department of Pathology, Immunology, and Laboratory Medicine, University of Florida Diabetes Institute, Gainesville, Florida, USA
| | - Alice E. Wiedeman
- Center for Translational Research, Benaroya Research Institute, Seattle, Washington, USA
| | - Kirsten Diggins
- Center for Translational Research, Benaroya Research Institute, Seattle, Washington, USA
| | - Adeeb Rahman
- Human Immune Monitoring Center, Hess Center for Science and Medicine, Icahn School of Medicine, New York, New York, USA
| | - Timothy I. M. Tree
- Department of Immunobiology, Faculty of Life Sciences & Medicine, King’s College, London, UK
- National Institute of Health Research Biomedical Research Centre at Guy’s and St. Thomas’ National Health Service Foundation Trust, King’s College London, London, UK
| | - Todd M. Brusko
- Department of Pathology, Immunology, and Laboratory Medicine, University of Florida Diabetes Institute, Gainesville, Florida, USA
- Department of Pediatrics, University of Florida Diabetes Institute, Gainesville, FL, USA
| | - Megan K. Levings
- Department of Surgery, University of British Columbia, Vancouver, California, USA
- BC Children’s Hospital Research Institute, Vancouver, California, USA
- School of Biomedical Engineering, University of British Columbia, California, USA
| | - Eddie A. James
- Center for Translational Research, Benaroya Research Institute, Seattle, Washington, USA
| | - Sally C. Kent
- Diabetes Center of Excellence, University of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA
| | - Cate Speake
- Center for Interventional Immunology, Benaroya Research Institute, Seattle, Washington, USA
| | - Dirk Homann
- Precision Immunology Institute, Icahn School of Medicine, New York, New York, USA
- Diabetes, Obesity, & Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - S. Alice Long
- Center for Translational Research, Benaroya Research Institute, Seattle, Washington, USA
| | | |
Collapse
|
254
|
Wang Y, Krémer V, Iannascoli B, Goff ORL, Mancardi DA, Ramke L, de Chaisemartin L, Bruhns P, Jönsson F. Specificity of mouse and human Fcgamma receptors and their polymorphic variants for IgG subclasses of different species. Eur J Immunol 2022; 52:753-759. [PMID: 35133670 DOI: 10.1002/eji.202149766] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2021] [Revised: 01/19/2022] [Accepted: 01/24/2022] [Indexed: 11/05/2022]
Abstract
Immunoglobulin G (IgG) is the predominant antibody class generated during infections and used for the generation of therapeutic antibodies. Antibodies are mainly characterized in or generated from animal models that support particular infections, respond to particular antigens or allow the generation of hybridomas. Due to the availability of numerous transgenic mouse models and the ease of performing bioassays with human blood cells in vitro, most antibodies from species other than mice and humans are tested in vitro using human cells and/or in vivo using mice. In this process, it is expected, but not yet systematically documented, that IgG from these species interact with human or mouse IgG receptors (FcγRs). In this study, we undertook a systematic assessment of binding specificities of IgG from various species to the families of mouse and human FcγRs, including their polymorphic variants. Our results document the specific binding patterns for each of these IgG (sub)classes, reveal possible caveats of antibody-based immunoassays, and will be a useful reference for the transition from one animal model to preclinical mouse models or human cell-based bioassays. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Yu Wang
- Institut Pasteur, Université de Paris, Unit of Antibodies in Therapy and Pathology, Inserm UMR1222, Paris, F-75015
| | - Vanessa Krémer
- Institut Pasteur, Université de Paris, Unit of Antibodies in Therapy and Pathology, Inserm UMR1222, Paris, F-75015
| | - Bruno Iannascoli
- Institut Pasteur, Université de Paris, Unit of Antibodies in Therapy and Pathology, Inserm UMR1222, Paris, F-75015
| | - Odile Richard-Le Goff
- Institut Pasteur, Université de Paris, Unit of Antibodies in Therapy and Pathology, Inserm UMR1222, Paris, F-75015
| | - David A Mancardi
- Institut Pasteur, Université de Paris, Unit of Antibodies in Therapy and Pathology, Inserm UMR1222, Paris, F-75015
| | - Leoni Ramke
- Institut Pasteur, Université de Paris, Unit of Antibodies in Therapy and Pathology, Inserm UMR1222, Paris, F-75015
| | - Luc de Chaisemartin
- Institut Pasteur, Université de Paris, Unit of Antibodies in Therapy and Pathology, Inserm UMR1222, Paris, F-75015.,APHP, Bichat Hospital, Immunology Department, Paris, F-75018
| | - Pierre Bruhns
- Institut Pasteur, Université de Paris, Unit of Antibodies in Therapy and Pathology, Inserm UMR1222, Paris, F-75015
| | - Friederike Jönsson
- Institut Pasteur, Université de Paris, Unit of Antibodies in Therapy and Pathology, Inserm UMR1222, Paris, F-75015.,CNRS, Paris, F-75016
| |
Collapse
|
255
|
Lückemeier P, Molter KL, Jarosch S, Huppertz P, Purcarea A, Effenberger MJP, Nauerth M, D'Ippolito E, Schober K, Busch DH. Global k off -rates of polyclonal T cell populations merge subclonal avidities and predict functionality. Eur J Immunol 2022; 52:582-596. [PMID: 35099805 DOI: 10.1002/eji.202149597] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2021] [Revised: 12/07/2021] [Accepted: 01/24/2022] [Indexed: 11/07/2022]
Abstract
The avidity of T cell receptors (TCRs) for peptide-major histocompatibility complexes (pMHCs) is a governing factor in how T cells respond to antigen. TCR avidity is generally linked to T cell functionality and there is growing evidence for distinct roles of low and high avidity T cells in different phases of immune responses. While physiological immune responses and many therapeutic T cell products targeting infections or cancers consist of polyclonal T cell populations with a wide range of individual avidities, the role of T cell avidity is usually investigated only in monoclonal experimental settings. In this report, we induced polyclonal T cell responses with a wide range of avidities towards a model epitope by altered peptide ligands (APL), and benchmarked global avidity of physiological polyclonal populations by investigation of TCR-pMHC koff -rates. We then investigated how varying sizes and avidities of monoclonal subpopulations translate into global koff -rates. Global koff -rates integrate subclonal avidities in a predictably weighted manner and robustly correlate with the functionality of murine polyclonal T cell populations in vitro and in vivo. Surveying the full avidity spectrum is essential to accurately assess polyclonal immune responses and inform the design of polyclonal T cell therapeutics. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Philipp Lückemeier
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München (TUM), Munich, Germany
| | - Katherine L Molter
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München (TUM), Munich, Germany
| | - Sebastian Jarosch
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München (TUM), Munich, Germany
| | - Patrick Huppertz
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München (TUM), Munich, Germany
| | - Anna Purcarea
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München (TUM), Munich, Germany
| | - Manuel J P Effenberger
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München (TUM), Munich, Germany
| | - Magdalena Nauerth
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München (TUM), Munich, Germany
| | - Elvira D'Ippolito
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München (TUM), Munich, Germany
| | - Kilian Schober
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München (TUM), Munich, Germany.,Mikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Wasserturmstraße 3/5, D-91054, Erlangen, Germany
| | - Dirk H Busch
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München (TUM), Munich, Germany
| |
Collapse
|
256
|
Sudworth A, Segers FM, Yilmaz B, Guslund NC, Macpherson AJ, Dissen E, Qiao SW, Inngjerdingen M. Innate lymphoid cell characterization in the rat and their correlation to gut commensal microbes. Eur J Immunol 2022; 52:717-729. [PMID: 35099074 DOI: 10.1002/eji.202149639] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Revised: 01/03/2022] [Accepted: 01/24/2022] [Indexed: 11/08/2022]
Abstract
Innate lymphoid cells (ILCs) are important for tissue immune homeostasis, and are thoroughly characterized in mice and humans. Here, we have performed in-depth characterization of rat ILCs. Rat ILCs were identified based on differential expression of transcription factors and lack of lineage markers. ILC3s represented the major ILC population of the small intestine, while ILC2s were infrequent but most prominent in liver. Two major subsets of group 1 ILCs were defined. Lineage- T-bet+ Eomes+ cells were identified as conventional NK cells, while lineage- T-bet+ Eomes- cells were identified as the probable rat counterpart of ILC1s based on their selective expression of the ILC marker CD200R. Rat ILC1s were particularly abundant in liver and intestinal tissues, and were functionally similar to NK cells. Single cell transcriptomics of spleen and liver cells confirmed the main division of NK cells and ILC1-like cells, and demonstrated Granzyme A as additional ILC1 marker. We further report differential distributions of NK cells and ILCs along the small and large intestines, and the association of certain bacterial taxa to frequencies of ILCs. In conclusion, we provide a framework for future studies of ILCs in diverse rat experimental models, and novel data on the potential interplay between commensals and intestinal ILCs. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Amanda Sudworth
- Department of Pharmacology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Filip M Segers
- Department of Pharmacology, Oslo University Hospital, Oslo, Norway
| | - Bahtiyar Yilmaz
- Department for Biomedical Research, University of Bern, Inselspital, Bern, Switzerland
| | - Naomi C Guslund
- Department of Immunology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Andrew J Macpherson
- Department for Biomedical Research, University of Bern, Inselspital, Bern, Switzerland
| | - Erik Dissen
- Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
| | - Shuo-Wang Qiao
- Department of Immunology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Marit Inngjerdingen
- Department of Pharmacology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.,Department of Pharmacology, Oslo University Hospital, Oslo, Norway
| |
Collapse
|
257
|
van der Donk LEH, Eder J, van Hamme JL, Brouwer PJM, Brinkkemper M, van Nuenen AC, van Gils MJ, Sanders RW, Kootstra NA, Bermejo-Jambrina M, Geijtenbeek TBH. SARS-CoV-2 infection activates dendritic cells via cytosolic receptors rather than extracellular TLRs. Eur J Immunol 2022; 52:646-655. [PMID: 35099061 PMCID: PMC9015339 DOI: 10.1002/eji.202149656] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Revised: 12/22/2021] [Accepted: 01/21/2022] [Indexed: 12/15/2022]
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) causes coronavirus disease 2019 (COVID‐19), an infectious disease characterized by strong induction of inflammatory cytokines, progressive lung inflammation, and potentially multiorgan dysfunction. It remains unclear how SARS‐CoV‐2 infection leads to immune activation. The Spike (S) protein of SARS‐CoV‐2 has been suggested to trigger TLR4 and thereby activate immunity. Here, we have investigated the role of TLR4 in SARS‐CoV‐2 infection and immunity. Neither exposure of isolated S protein, SARS‐CoV‐2 pseudovirus nor primary SARS‐CoV‐2 isolate induced TLR4 activation in a TLR4‐expressing cell line. Human monocyte‐derived DCs express TLR4 but not angiotensin converting enzyme 2 (ACE2), and DCs were not infected by SARS‐CoV‐2. Notably, neither S protein nor SARS‐CoV‐2 induced DC maturation or cytokines, indicating that both S protein and SARS‐CoV‐2 virus particles do not trigger extracellular TLRs including TLR4. Ectopic expression of ACE2 in DCs led to efficient infection by SARS‐CoV‐2 and, strikingly, efficient type I IFN and cytokine responses. These data strongly suggest that not extracellular TLRs but intracellular viral sensors are key players in sensing SARS‐CoV‐2. These data imply that SARS‐CoV‐2 escapes direct sensing by TLRs, which might underlie the lack of efficient immunity to SARS‐CoV‐2 early during infection.
Collapse
Affiliation(s)
- Lieve E H van der Donk
- Department of Experimental Immunology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
| | - Julia Eder
- Department of Experimental Immunology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
| | - John L van Hamme
- Department of Experimental Immunology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
| | - Philip J M Brouwer
- Department of Medical Microbiology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
| | - Mitch Brinkkemper
- Department of Medical Microbiology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
| | - Ad C van Nuenen
- Department of Experimental Immunology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
| | - Marit J van Gils
- Department of Medical Microbiology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
| | - Rogier W Sanders
- Department of Medical Microbiology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.,Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY, 10021, USA
| | - Neeltje A Kootstra
- Department of Experimental Immunology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
| | - Marta Bermejo-Jambrina
- Department of Experimental Immunology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
| | - Teunis B H Geijtenbeek
- Department of Experimental Immunology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
| |
Collapse
|
258
|
Essen MF, Schlagwein N, den Hoven EM, Gijlswijk‐Janssen DJ, Lubbers R, den Bos RM, den Born J, Ruben JM, Trouw LA, Kooten C. Initial properdin binding contributes to alternative pathway activation at the surface of viable and necrotic cells. Eur J Immunol 2022; 52:597-608. [PMID: 35092629 PMCID: PMC9303752 DOI: 10.1002/eji.202149259] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Revised: 12/01/2021] [Accepted: 01/10/2022] [Indexed: 11/16/2022]
Abstract
Properdin, the only known positive regulator of the complement system, stabilizes the C3 convertase, thereby increasing its half‐life. In contrast to most other complement factors, properdin is mainly produced extrahepatically by myeloid cells. Recent data suggest a role for properdin as a pattern recognition molecule. Here, we confirmed previous findings of properdin binding to different necrotic cells including Jurkat T cells. Binding can occur independent of C3, as demonstrated by HAP‐1 C3 KO cells, excluding a role for endogenous C3. In view of the cellular source of properdin, interaction with myeloid cells was examined. Properdin bound to the surface of viable monocyte‐derived pro‐ and anti‐inflammatory macrophages, but not to DCs. Binding was demonstrated for purified properdin as well as fractionated P2, P3, and P4 properdin oligomers. Binding contributed to local complement activation as determined by C3 and C5b‐9 deposition on the cell surfaces and seems a prerequisite for alternative pathway activation. Interaction of properdin with cell surfaces could be inhibited with the tick protein Salp20 and by different polysaccharides, depending on sulfation and chain length. These data identify properdin as a factor interacting with different cell surfaces, being either dead or alive, contributing to the local stimulation of complement activation.
Collapse
Affiliation(s)
- Mieke F. Essen
- Div. of Nephrology and Transplant Medicine Dept. of Medicine Leiden University Medical Center Leiden The Netherlands
| | - Nicole Schlagwein
- Div. of Nephrology and Transplant Medicine Dept. of Medicine Leiden University Medical Center Leiden The Netherlands
| | - Elisa M.P. den Hoven
- Div. of Nephrology and Transplant Medicine Dept. of Medicine Leiden University Medical Center Leiden The Netherlands
| | - Daniëlle J. Gijlswijk‐Janssen
- Div. of Nephrology and Transplant Medicine Dept. of Medicine Leiden University Medical Center Leiden The Netherlands
| | - Rosalie Lubbers
- Department of Rheumatology Leiden University Medical Center Leiden The Netherlands
| | - Ramon M. den Bos
- Crystal and Structural Chemistry Bijvoet Center for Biomolecular Research Department of Chemistry Faculty of Science Utrecht University Utrecht The Netherlands
| | - Jacob den Born
- Department of Nephrology University Medical Center Groningen Groningen The Netherlands
| | - Jurjen M. Ruben
- Div. of Nephrology and Transplant Medicine Dept. of Medicine Leiden University Medical Center Leiden The Netherlands
| | - Leendert A. Trouw
- Department of Rheumatology Leiden University Medical Center Leiden The Netherlands
- Department of Immunology Leiden University Medical Center Leiden The Netherlands
| | - Cees Kooten
- Div. of Nephrology and Transplant Medicine Dept. of Medicine Leiden University Medical Center Leiden The Netherlands
| | | |
Collapse
|
259
|
Renner K, Neumayer S, Talke Y, Buchtler S, Schmidbauer K, Nimmerjahn F, Lux A, Winter F, Salewski JN, Mack M. B cell modulation with anti-CD79bantibodies ameliorates experimental autoimmune encephalitis in mice. Eur J Immunol 2021; 52:656-668. [PMID: 34962287 DOI: 10.1002/eji.202149523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2021] [Revised: 11/15/2021] [Accepted: 12/28/2021] [Indexed: 11/12/2022]
Abstract
B cells play a major role in the pathogenesis of many autoimmune diseases like multiple sclerosis, rheumatoid arthritis or systemic lupus erythematosus. Depletion of B cells with anti-CD20 antibodies is an established therapy for multiple sclerosis. However, total B cell depletion will also affect regulatory B cells that are known to suppress autoimmune responses. In our studies we describe an alternative approach based on targeting of CD79b that induces only partial B cell depletion and achieves therapeutic effects by B cell modulation. Prophylactic and therapeutic treatment with an antibody against CD79b and also a deglycosylated variant of this antibody, lacking effector function like antibody-dependent cellular cytotoxicity or complement activation, significantly reduced the development and progression of experimental autoimmune encephalitis (EAE) in mice. Our data show that modulation of B cells via CD79b is equally effective as almost complete B cell depletion with anti-CD20 antibodies and may constitute an alternative approach to treat multiple sclerosis. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Kerstin Renner
- Department of Internal Medicine II - Nephrology, University Hospital Regensburg, Franz-Josef-Strauss Allee 11, Regensburg, 93042, Germany
| | - Sophia Neumayer
- Department of Internal Medicine II - Nephrology, University Hospital Regensburg, Franz-Josef-Strauss Allee 11, Regensburg, 93042, Germany
| | - Yvonne Talke
- Department of Internal Medicine II - Nephrology, University Hospital Regensburg, Franz-Josef-Strauss Allee 11, Regensburg, 93042, Germany
| | - Simone Buchtler
- Department of Internal Medicine II - Nephrology, University Hospital Regensburg, Franz-Josef-Strauss Allee 11, Regensburg, 93042, Germany
| | - Kathrin Schmidbauer
- Department of Internal Medicine II - Nephrology, University Hospital Regensburg, Franz-Josef-Strauss Allee 11, Regensburg, 93042, Germany
| | - Falk Nimmerjahn
- Division of Genetics, Department of Biology, University Erlangen-Nuernberg, Erwin-Rommel-Strasse 3, Erlangen, 91058, Germany
| | - Anja Lux
- Division of Genetics, Department of Biology, University Erlangen-Nuernberg, Erwin-Rommel-Strasse 3, Erlangen, 91058, Germany
| | - Frederike Winter
- Department of Internal Medicine II - Nephrology, University Hospital Regensburg, Franz-Josef-Strauss Allee 11, Regensburg, 93042, Germany.,Regensburg Center for Interventional Immunology, Franz-Josef-Strauss Allee 11, Regensburg, 93042, Germany
| | - Jan-Nicklas Salewski
- Department of Internal Medicine II - Nephrology, University Hospital Regensburg, Franz-Josef-Strauss Allee 11, Regensburg, 93042, Germany
| | - Matthias Mack
- Department of Internal Medicine II - Nephrology, University Hospital Regensburg, Franz-Josef-Strauss Allee 11, Regensburg, 93042, Germany.,Regensburg Center for Interventional Immunology, Franz-Josef-Strauss Allee 11, Regensburg, 93042, Germany
| |
Collapse
|
260
|
Mielle J, Morel J, ElHmioui J, Combe B, Macia L, Dardalhon V, Taylor N, Audo R, Daien C. Glutamine promotes the generation of B10 + cells via the mTOR/GSK3 pathway. Eur J Immunol 2021; 52:418-430. [PMID: 34961940 DOI: 10.1002/eji.202149387] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Revised: 11/23/2021] [Accepted: 12/20/2021] [Indexed: 11/06/2022]
Abstract
Alterations in cell metabolism can shift the differentiation of immune cells towards a regulatory or inflammatory phenotype, thus opening up new therapeutic opportunities for immune-related diseases. Indeed, growing knowledge on T cell metabolism has revealed differences in the metabolic programs of suppressive regulatory T cells (Tregs) as compared to inflammatory Th1 and Th17 cells. In addition to Tregs, IL-10-producing regulatory B cells are crucial for maintaining tolerance, inhibiting inflammation and autoimmunity. Yet, the metabolic networks regulating diverse B lymphocyte responses are not well known. Here, we show that glutaminase blockade decreased downstream mTOR activation and attenuated IL-10 secretion. Direct suppression of mTOR activity by rapamycin selectively impaired IL-10 production by B cells whereas secretion was restored upon GSK3 inhibition. Mechanistically, we found mTORC1 activation leads to GSK3 inhibition, identifying a key signalling pathway regulating IL-10 secretion by B lymphocytes. Thus, our results identify glutaminolysis and the mTOR/GSK3 signalling axis, as critical regulators of the generation of IL-10 producing B cells with regulatory functions. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Julie Mielle
- Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France.,Department of Rheumatology, CHU de Montpellier, Montpellier, France
| | - Jacques Morel
- Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France.,Department of Rheumatology, CHU de Montpellier, Montpellier, France.,PhyMedExp, University of Montpellier, INSERM, CNRS UMR, Montpellier, France
| | - Jamila ElHmioui
- Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France
| | - Bernard Combe
- Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France.,Department of Rheumatology, CHU de Montpellier, Montpellier, France.,PhyMedExp, University of Montpellier, INSERM, CNRS UMR, Montpellier, France
| | - Laurence Macia
- Charles Perkins Centre, the University of Sydney, Sydney, Australia.,School of Medical Sciences, Faculty of Medicine and Health, Sydney, Australia
| | - Valérie Dardalhon
- Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France
| | - Naomi Taylor
- Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France
| | - Rachel Audo
- Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France.,Department of Rheumatology, CHU de Montpellier, Montpellier, France.,PhyMedExp, University of Montpellier, INSERM, CNRS UMR, Montpellier, France
| | - Claire Daien
- Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France.,Department of Rheumatology, CHU de Montpellier, Montpellier, France.,PhyMedExp, University of Montpellier, INSERM, CNRS UMR, Montpellier, France
| |
Collapse
|